CN Patent
CN116496280B — 氘代丙烯酰胺类jak3抑制剂药物及用途
Assigned to Henan Yaokang Zhongtuo Pharmaceutical Technology Co ltd · Expires 2023-09-08 · 3y expired
What this patent protects
本发明提供了氘代丙烯酰胺类JAK3抑制剂的氘代化合物及其药学上可接受的盐,显著提高了对JAK3酶的抑制活性,进一步改善JAK3抑制剂的药代动力学性质,降低给药剂量和可能的毒副作用。本发明所述一种如下式Ⅰ所示的JAK3抑制剂的氘代丙烯酰胺类化合物,其结构如下: 。
USPTO Abstract
本发明提供了氘代丙烯酰胺类JAK3抑制剂的氘代化合物及其药学上可接受的盐,显著提高了对JAK3酶的抑制活性,进一步改善JAK3抑制剂的药代动力学性质,降低给药剂量和可能的毒副作用。本发明所述一种如下式Ⅰ所示的JAK3抑制剂的氘代丙烯酰胺类化合物,其结构如下: 。
Drugs covered by this patent
- Litfulo (Ritlecitinib Tosylate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.